dexamethasone,axicabtagene ciloleucel,nivolumab,pembrolizumab,varlilumab,lenalidomide
merck,bms,celldex,gilead,daiichi sankyo
['zuma-7', 'nivolumab', 'nivo', 'pembro', 'axi-cel', 'lenalidomide', 'axicabtagene ciloleucel', 'lymsm', 'dexamethasone', 'varlilumab', 'dlbcl', 'crispr']
zuma-7 third line data r/r dlbcl post axi-cel
chemo: 25% orr, 13% crr
slightly better outcomes for 8 pts who got second round of car-t
10/60 chemo pts underwent asct so is feasible in minority who remain chemosensitive
#ash22 #lymsm 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer